The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
One-step high-efficiency CRISPR/Cas9-mediated genome editing in Streptomyces
Abstract
The RNA-guided DNA editing technology CRISPRs (clustered regularly interspaced short palindromic repeats)/Cas9 had been used to introduce double-stranded breaks into genomes and to direct subsequent site-specific insertions/deletions or the replacement of genetic material in bacteria, such as Escherichia coli, Streptococcus pneumonia, and Lactobacillus reuteri. In this study, we established a high-efficiency CRISPR/Cas9 genome editing plasmid pKCcas9dO for use in Streptomyces genetic manipulation, which comprises a target-specific guide RNA, a codon-optimized cas9, and two homology-directed repair templates. By delivering pKCcas9dO series editing plasmids into the model strain Streptomyces coelicolor M145, through one-step intergeneric transfer, we achieved the genome editing at different levels with high efficiencies of 60%-100%, including single gene deletion, such as actII-orf4, redD, and glnR, and single large-size gene cluster deletion, such as the antibiotic biosynthetic clusters of actinorhodin (ACT) (21.3 kb), undecylprodigiosin (RED) (31.6 kb), and Ca(2+)-dependent antibiotic (82.8 kb). Furthermore, we also realized simultaneous deletions of actII-orf4 and redD, and of the ACT and RED biosynthetic gene clusters with high efficiencies of 54% and 45%, respectively. Finally, we applied this system to introduce nucleotide point mutations into the rpsL gene, which conferred the mutants with resistance to streptomycin. Notably, using this system, the time required for one round of genome modification is reduced by one-third or one-half of those for conventional methods. These results clearly indicate that the established CRISPR/Cas9 genome editing system substantially improves the genome editing efficiency compared with the currently existing methods in Streptomyces, and it has promise for application to genome modification in other Actinomyces species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationOne-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products
Datsenko, K. A., & Wanner, B. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120163297 · Cited by 14,782
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
Practical streptomyces genetics
Kieser, T. (2000) · Medical Entomology and Zoology · Cited by 3,923
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 1×
“The high efficiency and convenience of CRISPR/Cas9 technology favor its application in eukaryotic cells, and the off-target effects have drawn the attention of investigators in these systems [55–58].”
BackgroundBioactive Microbial Metabolites: A Personal View
Bérdy, J. (2005) · The Journal of Antibiotics · doi:10.1038/ja.2005.1 · Cited by 3,170
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,465
Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes
Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J. H., Snijders, A. P. L., Dickman, M. J., Makarova, K. S., Koonin, E. V., & van der Oost, J. (2008) · Science · doi:10.1126/science.1159689 · Cited by 2,460
RNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA
Garneau, J. E., Dupuis, M.-È., Villion, M., Romero, D. A., Barrangou, R., Boyaval, P., Fremaux, C., Horvath, P., Magadán, A. H., & Moineau, S. (2010) · Nature · doi:10.1038/nature09523 · Cited by 2,328
RNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems
DiCarlo, J. E., Norville, J. E., Mali, P., Rios, X., Aach, J., & Church, G. M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt135 · Cited by 1,566
Bolotin, A., Quinquis, B., Sorokin, A., & Ehrlich, S. D. (2005) · Microbiology · doi:10.1099/mic.0.28048-0 · Cited by 1,558
Li, J.-F., Norville, J. E., Aach, J., McCormack, M., Zhang, D., Bush, J., Church, G. M., & Sheen, J. (2013) · Nature Biotechnology · doi:10.1038/nbt.2654 · Cited by 1,510
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487
Gust, B., Challis, G. L., Fowler, K., Kieser, T., & Chater, K. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337542100 · Cited by 1,416
Multigene editing in the Escherichia coli genome via the CRISPR-Cas9 system
Jiang, Y., Chen, B., Duan, C., Sun, B., Yang, J., & Yang, S. (2015) · Applied and Environmental Microbiology · doi:10.1128/aem.04023-14 · Cited by 1,362
CRISPR interference (CRISPRi) for sequence-specific control of gene expression
Larson, M. H., Gilbert, L. A., Wang, X., Lim, W. A., Weissman, J. S., & Qi, L. S. (2013) · Nature Protocols · doi:10.1038/nprot.2013.132 · Cited by 1,212
RNA-Guided RNA Cleavage by a CRISPR RNA-Cas Protein Complex
Hale, C. R., Zhao, P., Olson, S., Duff, M. O., Graveley, B. R., Wells, L., Terns, R. M., & Terns, M. P. (2009) · Cell · doi:10.1016/j.cell.2009.07.040 · Cited by 1,031
Genome Engineering of Drosophila with the CRISPR RNA-Guided Cas9 Nuclease
Gratz, S. J., Cummings, A. M., Nguyen, J. N., Hamm, D. C., Donohue, L. K., Harrison, M. M., Wildonger, J., & O’Connor-Giles, K. M. (2013) · Genetics · doi:10.1534/genetics.113.152710 · Cited by 976
Fast and Efficient Estimation of Individual Ancestry Coefficients
Frichot, E., Mathieu, F., Trouillon, T., Bouchard, G., & François, O. (2014) · Genetics · doi:10.1534/genetics.113.160572 · Cited by 931
Highly Specific and Efficient CRISPR/Cas9-Catalyzed Homology-Directed Repair in Drosophila
Gratz, S. J., Ukken, F. P., Rubinstein, C. D., Thiede, G., Donohue, L. K., Cummings, A. M., & O’Connor-Giles, K. M. (2014) · Genetics · doi:10.1534/genetics.113.160713 · Cited by 927
How many antibiotics are produced by the genus Streptomyces ?
Watve, M., Tickoo, R., Jog, M., & Bhole, B. (2001) · Archives of Microbiology · doi:10.1007/s002030100345 · Cited by 923
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
Wang, J., Soisson, S. M., Young, K., Shoop, W., Kodali, S., Galgoci, A., Painter, R., Parthasarathy, G., Tang, Y. S., Cummings, R., et al. (2006) · Nature · doi:10.1038/nature04784 · Cited by 812
Genomic basis for natural product biosynthetic diversity in the actinomycetes
Nett, M., Ikeda, H., & Moore, B. S. (2009) · Natural Product Reports · doi:10.1039/b817069j · Cited by 757
Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis
Hou, Z., Zhang, Y., Propson, N. E., Howden, S. E., Chu, L.-F., Sontheimer, E. J., & Thomson, J. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313587110 · Cited by 681
Lin, Y., Cradick, T. J., Brown, M. T., Deshmukh, H., Ranjan, P., Sarode, N., Wile, B. M., Vertino, P. M., Stewart, F. J., & Bao, G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku402 · Cited by 634 · cited 1×
“The high efficiency and convenience of CRISPR/Cas9 technology favor its application in eukaryotic cells, and the off-target effects have drawn the attention of investigators in these systems [55–58].”
BackgroundCobb, R. E., Wang, Y., & Zhao, H. (2015) · ACS Synthetic Biology · doi:10.1021/sb500351f · Cited by 570
Udwary, D. W., Zeigler, L., Asolkar, R. N., Singan, V., Lapidus, A., Fenical, W., Jensen, P. R., & Moore, B. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700962104 · Cited by 536
Genome-minimized Streptomyces host for the heterologous expression of secondary metabolism
Komatsu, M., Uchiyama, T., Ōmura, S., Cane, D. E., & Ikeda, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914833107 · Cited by 500
Renaissance in antibacterial discovery from actinomycetes
BALTZ, R. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.04.008 · Cited by 498
Pharmaceutically active secondary metabolites of microorganisms
Demain, A. L. (1999) · Applied Microbiology and Biotechnology · doi:10.1007/s002530051546 · Cited by 483
CRISPR–Cas9-assisted recombineering in Lactobacillus reuteri
Oh, J.-H., & van Pijkeren, J.-P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku623 · Cited by 392
Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system
Sakuma, T., Nishikawa, A., Kume, S., Chayama, K., & Yamamoto, T. (2014) · Scientific Reports · doi:10.1038/srep05400 · Cited by 352
Antitumor compounds from marine actinomycetes
Olano, C., Méndez, C., & Salas, J. A. (2009) · Marine Drugs · doi:10.3390/md7020210 · Cited by 330 · cited 1×
“They produce many compounds with various structures and biological activities, including antibacterial, antifungal, immunosuppressive, anticancer, and antivirus activities, which are major sources of clinically important medicines and are lead candidates for new drug development [1–10].”
BackgroundGenomics-inspired discovery of natural products
Winter, J. M., Behnken, S., & Hertweck, C. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.10.020 · Cited by 243
Shima, J., Hesketh, A., Okamoto, S., Kawamoto, S., & Ochi, K. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.24.7276-7284.1996 · Cited by 243
Singh, S. B., Jayasuriya, H., Ondeyka, J. G., Herath, K. B., Zhang, C., Zink, D. L., Tsou, N. N., Ball, R. G., Basilio, A., Genilloud, O., et al. (2006) · Journal of the American Chemical Society · doi:10.1021/ja062232p · Cited by 232
McAlpine, J. B., Bachmann, B. O., Piraee, M., Tremblay, S., Alarco, A.-M., Zazopoulos, E., & Farnet, C. M. (2005) · Journal of Natural Products · doi:10.1021/np0401664 · Cited by 231
Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis.
Goto, T., KINO, T., Hatanaka, H., Nishiyama, M., OKUHARA, M., KOHSAKA, M., Aoki, H., & Imanaka, H. (1987) · PubMed · Cited by 216
Current approaches to exploit actinomycetes as a source of novel natural products
Genilloud, O., González, I., Salazar, O., Martín, J., Tormo, J. R., & Vicente, F. (2011) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-010-0882-7 · Cited by 203
Tiffert, Y., Supra, P., Wurm, R., Wohlleben, W., Wagner, R., & Reuther, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.06092.x · Cited by 201
Zhu, L. J., Holmes, B. R., Aronin, N., & Brodsky, M. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108424 · Cited by 195
Road to precision: recombinase-based targeting technologies for genome engineering
Wirth, D., Gama-Norton, L., Riemer, P., Sandhu, U., Schucht, R., & Häuser, H. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.07.013 · Cited by 175
Small‐molecule elicitation of microbial secondary metabolites
Pettit, R. K. (2011) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2010.00196.x · Cited by 162
Fink, D., Weißschuh, N., Reuther, J., Wohlleben, W., & Engels, A. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03150.x · Cited by 157
Emerging novel antifungal agents
Fostel, J. M., & Lartey, P. A. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01430-0 · Cited by 123
Toward design-based engineering of industrial microbes
Tyo, K. E. J., Kocharin, K., & Nielsen, J. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.02.001 · Cited by 92
Hair, P. I., & Keam, S. J. (2007) · Drugs · doi:10.2165/00003495-200767100-00008 · Cited by 90
Synthetic Biology of Antimicrobial Discovery
Zakeri, B., & Lu, T. K. (2012) · ACS Synthetic Biology · doi:10.1021/sb300101g · Cited by 53
Streamlining genomes: toward the generation of simplified and stabilized microbial systems
Leprince, A., van Passel, M. W. J., & dos Santos, V. A. P. M. (2012) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2012.05.001 · Cited by 39
Semi‐Synthetic Mithramycin SA Derivatives with Improved AntiCancer Activity
Scott, D. F., Chen, J., Bae, Y., & Rohr, J. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12107 · Cited by 24
Characterizing CRISPR off-target effects
Burgess, D. J. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3651 · Cited by 4
Cited by
CRISPR-Cas immunity in prokaryotes
Marraffini, L. A. (2015) · Nature · doi:10.1038/nature15386 · Cited by 829
Synthetic biology to access and expand nature's chemical diversity
Smanski, M. J., Zhou, H., Claesen, J., Shen, B., Fischbach, M. A., & Voigt, C. A. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2015.24 · Cited by 481
CRISPR–Cas9 strategy for activation of silent Streptomyces biosynthetic gene clusters
Zhang, M. M., Wong, F. T., Wang, Y., Luo, S., Lim, Y. H., Heng, E., Yeo, W. L., Cobb, R. E., Enghiad, B., Ang, E. L., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2341 · Cited by 304
Consequences of Cas9 cleavage in the chromosome of Escherichia coli
Cui, L., & Bikard, D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw223 · Cited by 276
Nidhi, S., Anand, U., Oleksak, P., Tripathi, P., Lal, J. A., Thomas, G., Kuca, K., & Tripathi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073327 · Cited by 276
Metadata
- Authors
- Huang, H., Zheng, G., Jiang, W., Hu, H., & Lu, Y.
- Venue
- Acta Biochimica et Biophysica Sinica
- Published
- 2015-04-01
- Volume
- 47
- Issue
- 4
- Pages
- 231-243
- ISSN
- 1672-9145 (ISSN-L)
- OpenAlex
- W2143999510
- Cited by
- 289
- References
- 58
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.